Monoclonal Antibody Therapeutics
•150 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (150)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly relies on monoclonal antibody therapeutics across indications.
|
$946.66B |
$1001.01
-0.73%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$587.17B |
$243.70
+0.46%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$401.21B |
$226.96
-0.22%
|
|
AZN
AstraZeneca PLC
AZN develops monoclonal antibody therapeutics across oncology and immunology.
|
$302.23B |
$195.07
+0.06%
|
|
MRK
Merck & Co., Inc.
Keytruda and other antibody therapies place Merck in monoclonal antibody therapeutics.
|
$290.62B |
$117.11
+0.00%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$202.16B |
$375.64
-0.35%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy’s antibody component and other cancer therapies align with Monoclonal Antibody Therapeutics.
|
$184.32B |
$148.62
+1.36%
|
|
PFE
Pfizer Inc.
Monoclonal antibody therapeutics represent a major therapeutic modality in Pfizer's portfolio and oncology pipeline.
|
$154.42B |
$27.16
+1.31%
|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$122.41B |
$60.15
-0.79%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$81.14B |
$772.27
-1.19%
|
|
TAK
Takeda Pharmaceutical Company Limited
Entrvyo/vedolizumab and other monoclonal antibody therapies place Takeda in Monoclonal Antibody Therapeutics.
|
$56.89B |
$18.20
+0.75%
|
|
ZTS
Zoetis Inc.
Zoetis employs monoclonal antibodies for OA pain and dermatology therapies (e.g., Librela, Solensia, Cytopoint), defining a core Monoclonal Antibody Therapeutics product line.
|
$53.10B |
$120.48
-1.54%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$45.34B |
$742.53
+0.29%
|
|
ONC
BeOne Medicines Ltd.
TEVIMBRA is a monoclonal antibody therapy, placing the company in monoclonal antibody therapeutics.
|
$33.83B |
$305.50
+1.06%
|
|
BIIB
Biogen Inc.
Biogen's portfolio includes monoclonal antibody therapeutics (e.g., LEQEMBI) as a core modality.
|
$27.64B |
$188.50
+0.14%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$20.66B |
$29.73
+0.68%
|
|
BNTX
BioNTech SE
The company develops monoclonal antibody therapeutics (including bispecifics) for cancer, a core product area.
|
$20.17B |
$84.11
-17.67%
|
|
INCY
Incyte Corporation
Monoclonal Antibody Therapeutics is a direct product modality for Monjuvi (tafasitamab) and similar antibody-based cancer therapies.
|
$18.85B |
$96.00
-1.13%
|
|
GMAB
Genmab A/S
Genmab develops and commercializes monoclonal antibody therapeutics (e.g., antibody-based oncology medicines).
|
$17.95B |
$27.96
+2.64%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is an antibody-based therapeutic, aligning with Monoclonal Antibody Therapeutics as a core modality.
|
$12.16B |
$16.33
+3.88%
|
|
RDY
Dr. Reddy's Laboratories Limited
Monoclonal antibody therapeutics emphasis via biosimilar strategies (e.g., abatacept, rituximab, pembrolizumab collaboration).
|
$11.99B |
$14.51
+0.80%
|
|
ELAN
Elanco Animal Health Incorporated
Monoclonal Antibody Therapeutics platform (CPMA and IL‑31 related programs) constitutes a key technology and product approach.
|
$11.76B |
$23.67
-1.13%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$11.30B |
$185.93
+0.29%
|
|
MRUS
Merus N.V.
Core product category: monoclonal antibody therapeutics used in cancer indications.
|
$6.81B |
$90.00
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$5.15B |
$75.41
+0.63%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$4.65B |
$29.29
+0.34%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.57B |
$44.72
+1.10%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.51B |
$25.71
-2.65%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$3.73B |
$86.82
+9.58%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody is an antibody-based platform; its advances map to 'Monoclonal Antibody Therapeutics'.
|
$3.70B |
$27.57
+5.65%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
KPL-387 is a monoclonal antibody targeting IL-1R1, placing the pipeline in monoclonal antibody therapeutics.
|
$3.56B |
$47.02
+0.60%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$3.23B |
$41.45
+0.93%
|
|
ALMS
Alumis Inc. Common Stock
Lonigutamab is a monoclonal antibody therapy, a direct product in the biopharma pipeline.
|
$2.92B |
$28.11
+4.73%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.79B |
$29.20
-1.50%
|
|
RCUS
Arcus Biosciences, Inc.
Domvanalimab is a monoclonal antibody therapeutic, placing Arcus in the Monoclonal Antibody Therapeutics category.
|
$2.65B |
$24.55
+4.80%
|
|
BEAM
Beam Therapeutics Inc.
BEAM-103 involves an anti-CD117 monoclonal antibody; includes Monoclonal Antibody Therapeutics as part of its conditioning strategy.
|
$2.65B |
$26.10
-5.50%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$2.57B |
$40.22
+3.19%
|
|
ADPT
Adaptive Biotechnologies Corporation
Monoclonal Antibody Therapeutics tag aligns with autoreactive TCR targeting and antibody programs.
|
$2.22B |
$14.53
-2.81%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
UX143 is a monoclonal antibody; Ultragenyx' portfolio includes monoclonal antibody therapeutics (Crysvita, Evkeeza, UX143).
|
$2.20B |
$22.85
+1.06%
|
|
ZLAB
Zai Lab Limited
Significant monoclonal antibody therapeutics activity across oncology/immunology assets.
|
$2.15B |
$19.46
+1.78%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Niktimvo axatilimab-csfr is a monoclonal antibody therapy, fitting Monoclonal Antibody Therapeutics.
|
$2.10B |
$24.16
+1.15%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$2.07B |
$31.15
+1.37%
|
|
IMNM
Immunome, Inc.
Antibody-based therapeutics component of ADCs justifies Monoclonal Antibody Therapeutics tagging.
|
$2.00B |
$21.89
+2.63%
|
|
ZYME
Zymeworks Inc.
Company develops monoclonal antibody therapeutics as a core modality.
|
$1.91B |
$25.45
+4.95%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.72B |
$62.02
+3.89%
|
|
OGN
Organon & Co.
Monoclonal antibody therapeutics including Emgality marketed within Organon's portfolio.
|
$1.68B |
$6.48
-0.77%
|
|
OCS
Oculis Holding AG
OCS-02 Licaminlimab is an antibody-based therapeutic (monoclonal antibody therapeutics).
|
$1.60B |
$28.62
+4.38%
|
|
VIR
Vir Biotechnology, Inc.
VIR's antibody-based approaches include monoclonal antibody therapeutics targeting cancer antigens.
|
$1.37B |
$9.88
+0.77%
|
|
NKTR
Nektar Therapeutics
NKTR-0165 is a monoclonal antibody therapeutic (TNFR2 agonist), aligning with Monoclonal Antibody Therapeutics.
|
$1.37B |
$72.05
+4.19%
|
|
KOD
Kodiak Sciences Inc.
Lead assets are monoclonal antibody therapeutics designed for retinal disease, aligning with Monoclonal Antibody Therapeutics.
|
$1.33B |
$25.08
-2.49%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
NRIX
Nurix Therapeutics, Inc.
The narrative references antibody therapies in addition to small molecule degraders, aligning with Monoclonal Antibody Therapeutics.
|
$1.22B |
$15.92
+2.71%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead product is a monoclonal antibody–type therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$1.09B |
$20.05
+1.78%
|
|
ZBIO
Zenas BioPharma, Inc.
Obexelimab is a monoclonal antibody therapeutic developed by the company.
|
$1.09B |
$25.92
-0.84%
|
|
BHVN
Biohaven Ltd.
BHVN's Trop2 ADC program aligns with Monoclonal Antibody Therapeutics as a core oncology modality.
|
$1.09B |
$10.27
+0.54%
|
|
ABCL
AbCellera Biologics Inc.
Company is developing monoclonal antibody therapeutics through wholly-owned programs ABCL635 and ABCL575.
|
$1.07B |
$3.58
+1.85%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
ADC programs involve monoclonal antibody components; ARR-217 implies monoclonal antibody therapeutics as part of the ADC strategy.
|
$1.05B |
$25.27
+1.87%
|
|
INBX
Inhibrx Biosciences, Inc.
Monoclonal antibody therapeutics addressing cancer targets with multivalent formats.
|
$1.04B |
$71.28
-0.81%
|
|
ERAS
Erasca, Inc.
ERAS-12 is an EGFR biparatopic antibody, constituting Monoclonal Antibody Therapeutics.
|
$1.02B |
$3.58
+6.07%
|
|
CMPX
Compass Therapeutics, Inc.
Company develops Monoclonal Antibody Therapeutics for oncology applications.
|
$990.69M |
$5.59
+3.14%
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$959.52M |
$57.99
-0.04%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
OPK
OPKO Health, Inc.
ModeX antibody therapies fall under monoclonal antibody therapeutics.
|
$913.56M |
$1.18
-2.48%
|
|
CGEM
Cullinan Therapeutics, Inc.
Antibody-based therapeutics (monoclonal antibodies) are a direct product modality for CLN-978 and velinotamig.
|
$880.80M |
$14.87
-2.91%
|
|
XNCR
Xencor, Inc.
Core output includes engineered monoclonal antibody therapeutics via the XmAb platform.
|
$855.50M |
$11.98
+0.93%
|
|
JANX
Janux Therapeutics, Inc.
Therapies revolve around monoclonal antibody-based modalities (including bispecific antibodies).
|
$846.28M |
$14.05
+0.54%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY therapeutics are monoclonal antibody–based biologics, aligning with Monoclonal Antibody Therapeutics.
|
$804.77M |
$4.87
-3.18%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$709.95M |
$12.56
-0.16%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Imsidolimab is a monoclonal antibody therapeutic targeting IL-36R for generalized pustular psoriasis.
|
$564.96M |
$9.55
+10.08%
|
|
ABSI
Absci Corporation
Internal programs ABS-101/ABS-201/ABS-301/ABS-501 are antibody-based therapeutics targeting oncology and immunology, aligning with Monoclonal Antibody Therapeutics.
|
$559.21M |
$3.87
+3.34%
|
|
ADCT
ADC Therapeutics S.A.
ZYNLONTA uses a monoclonal antibody as its targeting moiety, fitting Monoclonal Antibody Therapeutics.
|
$540.00M |
$4.79
+13.24%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$525.92M |
$9.76
-0.56%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
EBS
Emergent BioSolutions Inc.
Ebanga is a monoclonal antibody therapeutic developed by Emergent for Ebola; this aligns with the Monoclonal Antibody Therapeutics investable theme.
|
$440.64M |
$8.39
+0.48%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$437.74M |
$8.14
+0.99%
|
|
PRTC
PureTech Health plc
LYT-200 is a monoclonal antibody therapeutic, a core biologics modality.
|
$414.68M |
$17.16
+4.60%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's pipeline includes fully human monoclonal antibodies licensed from Vanderbilt, aligning with Monoclonal Antibody Therapeutics.
|
$404.57M |
$5.64
+0.80%
|
|
IMMP
Immutep Limited
IMP761 is described as a LAG-3 agonist antibody, aligning with Monoclonal Antibody Therapeutics.
|
$403.07M |
$2.75
-0.18%
|
|
ACRS
Aclaris Therapeutics, Inc.
Bosakitug and other assets are monoclonal antibody therapeutics, matching Monoclonal Antibody Therapeutics.
|
$397.63M |
$3.67
+8.26%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
DANYELZA (naxitamab-gqgk) is a monoclonal antibody therapeutic.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
Belrestotug is a monoclonal antibody targeting TIGIT, indicating direct production of monoclonal antibody therapeutics.
|
$388.48M |
$10.15
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 is a humanized monoclonal antibody targeting uPAR, fitting Monoclonal Antibody Therapeutics.
|
$380.87M |
$56.59
-8.33%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$377.15M |
$5.96
-1.00%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$351.48M |
$28.35
+1.32%
|
|
ANL
Adlai Nortye Ltd.
ANL’s antibody-based therapeutics position the company within Monoclonal Antibody Therapeutics as a related category.
|
$328.08M |
$9.00
+2.39%
|
|
ACIU
AC Immune S.A.
Monoclonal Antibody Therapeutics – AC Immune develops conformation-specific monoclonal antibodies via SupraAntigen platforms.
|
$305.92M |
$3.02
+5.77%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$297.66M |
$3.20
-1.84%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
VYGR
Voyager Therapeutics, Inc.
VY7523 is a monoclonal antibody targeting tau, category: Monoclonal Antibody Therapeutics.
|
$278.00M |
$5.00
+21.53%
|
|
CNTX
Context Therapeutics Inc.
CTX's products are therapeutic antibodies (monoclonal antibody therapeutics) used for cancer.
|
$261.94M |
$2.92
+0.52%
|
|
ZURA
Zura Bio Limited
Crebankitug and torudokimab are monoclonal antibodies in Zura Bio's pipeline (Monoclonal Antibody Therapeutics).
|
$261.37M |
$4.01
-0.25%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$259.78M |
$2.38
+8.45%
|
|
SRZN
Surrozen, Inc.
Company develops monoclonal antibody therapeutics targeting tissue-specific Wnt signaling.
|
$237.74M |
$27.97
+2.08%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$235.70M |
$1.95
+1.04%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
RNA
Avidity Biosciences, Inc.
Monoclonal Antibody Therapeutics: uses antibody component for targeting in the AOC platform.
|
$227.60M |
$14.81
+0.14%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$222.60M |
$16.86
-2.57%
|
|
STRO
Sutro Biopharma, Inc.
ADC therapies are a form of monoclonal antibody–based therapeutics, aligning with Sutro's antibody-drug conjugate products.
|
$215.58M |
$25.50
+2.08%
|
|
CGEN
Compugen Ltd.
COM701 and GS-0321 are monoclonal antibody therapeutics in development, aligning with Monoclonal Antibody Therapeutics.
|
$209.53M |
$2.23
+3.95%
|
Showing page 1 of 2 (150 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
